search
Back to results

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Primary Purpose

Diabete Type 2

Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Sitagliptin 50 mg
Empagliflozin 12.5 MG
Sitagliptin 50 mg + Empagliflozin 12.5 MG
Empagliflozin 12.5 MG + Sitagliptin 50 mg
Sponsored by
Sadat City University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabete Type 2

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 male/female diabetic patients
  • Age 20-70 years
  • A1C less than 10.5%

Exclusion Criteria:

  • Type 1 diabetes; HbA1c > 10.5%
  • Pregnancy
  • Chronic liver disease
  • Elevated (more than twofold the upper limit of normal) ALT, AST and CPK.
  • High bilirubin
  • Albumin < 3.5 g/dl
  • INR >1-2 Diabetic ketoacidosis
  • Urinary tract infection (UTI)
  • Pancreatitis < 6 months prior to enrolment
  • Renal impairment (creatinine clearance ≤50 ml/min)
  • Treatment with anti-obesity drugs or glucagon-like peptide-1 receptor agonists (GLP-1RAs) 3 months prior to enrolment
  • Non-compliance with follow-up visits.

Sites / Locations

  • University of Sadat City

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Sitagliptin 50 mg twice daily

Empagliflozin 12.5 twice daily

Sitagliptin 50 mg + empagliflozin 12.5 mg

Empagliflozin 12.5 + sitagliptin 50mg

Arm Description

sitagliptin 50 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.

Empagliflozin 12.5 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.

empagliflozin 12.5 mg is added to the patients with HbA1c 7-10 % of sitagliptin 50 mg group for another 12 weeks.

sitagliptin 50 mg is added to the patients with HbA1c 7-10 % of empagliflozin 12.5 mg group for another 12 weeks.

Outcomes

Primary Outcome Measures

Proportion of cured patients in the sitagliptin group versus the proportion of cured patients in the empagliflozin group
The primary efficacy endpoint will be evaluated as clinical cure after 12 weeks of addition of sitagliptin or empagliflozin to metformin and after 12 weeks after adding empaglifozin to sitagliptin group and vise versa. Clinical cure defined by A1C controlled (less than 7%), decrease in fasting and postprandial plasma glucose (mg/dl).

Secondary Outcome Measures

The decrease in the body weight in patients in sitagliptin group versus empagliflozin group
The decreased in body weight (Kg) from the baseline measures after therapy.
The decrease in blood pressure in patients in sitagliptin group versus empagliflozin group
decrease in blood pressure is defined as the decrease in SBP and/or DBP (mmHg) from the baseline measures after completing therapy
The change in lipid profile in patients in sitagliptin group versus empagliflozin group
Change in lipid profile including decreasing in the following measures from the baseline measures after therapy is completed: low density lipoprotein (mg/dl), total cholesterol (mg/dl), triglyceride (mg/dl) and high density lipoprotein (mg/dl).

Full Information

First Posted
April 5, 2022
Last Updated
April 27, 2022
Sponsor
Sadat City University
Collaborators
Beni-Suef University
search

1. Study Identification

Unique Protocol Identification Number
NCT05359341
Brief Title
Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?
Official Title
Comparative Study of DPP-4 Inhibitors and SGLT-2 Inhibitors in Egyptian Diabetic Patients
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
September 20, 2020 (Actual)
Primary Completion Date
September 20, 2021 (Actual)
Study Completion Date
January 10, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sadat City University
Collaborators
Beni-Suef University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Our trial goal is to determine the efficacy and safety of sitagliptin in comparison with empagliflozin in type 2 diabetic Egyptian patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabete Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
175 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sitagliptin 50 mg twice daily
Arm Type
Active Comparator
Arm Description
sitagliptin 50 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.
Arm Title
Empagliflozin 12.5 twice daily
Arm Type
Active Comparator
Arm Description
Empagliflozin 12.5 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.
Arm Title
Sitagliptin 50 mg + empagliflozin 12.5 mg
Arm Type
Active Comparator
Arm Description
empagliflozin 12.5 mg is added to the patients with HbA1c 7-10 % of sitagliptin 50 mg group for another 12 weeks.
Arm Title
Empagliflozin 12.5 + sitagliptin 50mg
Arm Type
Active Comparator
Arm Description
sitagliptin 50 mg is added to the patients with HbA1c 7-10 % of empagliflozin 12.5 mg group for another 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Sitagliptin 50 mg
Other Intervention Name(s)
DPP4 inhibitor
Intervention Description
Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Empagliflozin 12.5 MG
Other Intervention Name(s)
SGLT2 inhibitor
Intervention Description
Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Sitagliptin 50 mg + Empagliflozin 12.5 MG
Other Intervention Name(s)
DPP4 inhibitor + SGLT2 inhibitor
Intervention Description
Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)
Intervention Type
Drug
Intervention Name(s)
Empagliflozin 12.5 MG + Sitagliptin 50 mg
Other Intervention Name(s)
SGLT2 inhibitor + DPP4 inhibitor
Intervention Description
Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)
Primary Outcome Measure Information:
Title
Proportion of cured patients in the sitagliptin group versus the proportion of cured patients in the empagliflozin group
Description
The primary efficacy endpoint will be evaluated as clinical cure after 12 weeks of addition of sitagliptin or empagliflozin to metformin and after 12 weeks after adding empaglifozin to sitagliptin group and vise versa. Clinical cure defined by A1C controlled (less than 7%), decrease in fasting and postprandial plasma glucose (mg/dl).
Time Frame
After completion of the study (One year anticipated)
Secondary Outcome Measure Information:
Title
The decrease in the body weight in patients in sitagliptin group versus empagliflozin group
Description
The decreased in body weight (Kg) from the baseline measures after therapy.
Time Frame
After completion of the study (One year anticipated)
Title
The decrease in blood pressure in patients in sitagliptin group versus empagliflozin group
Description
decrease in blood pressure is defined as the decrease in SBP and/or DBP (mmHg) from the baseline measures after completing therapy
Time Frame
After completion of the study (One year anticipated)
Title
The change in lipid profile in patients in sitagliptin group versus empagliflozin group
Description
Change in lipid profile including decreasing in the following measures from the baseline measures after therapy is completed: low density lipoprotein (mg/dl), total cholesterol (mg/dl), triglyceride (mg/dl) and high density lipoprotein (mg/dl).
Time Frame
After completion of the study (One year anticipated)
Other Pre-specified Outcome Measures:
Title
Percentage of adverse effects appeared in patients in sitagliptin group versus percentage of adverse effects appear in patients in the empagliflozin group.
Description
AEs (n%) included all events with an onset after the first dose of open label emoagliflozin or sitagliptin and up to 7 days after the last dose of study drug. AEs of special interest included hypoglycaemia, genitourinary infections, hypersensitivity reactions, diabetic ketoacidosis, acute pancreatitis, hypotension, and dehydration. Confirmed hypoglycemic AEs were defined as events with a plasma glucose concentration of ≤ 3.9 mmol/L.
Time Frame
After completion of the study (One year anticipated)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 male/female diabetic patients Age 20-70 years A1C less than 10.5% Exclusion Criteria: Type 1 diabetes; HbA1c > 10.5% Pregnancy Chronic liver disease Elevated (more than twofold the upper limit of normal) ALT, AST and CPK. High bilirubin Albumin < 3.5 g/dl INR >1-2 Diabetic ketoacidosis Urinary tract infection (UTI) Pancreatitis < 6 months prior to enrolment Renal impairment (creatinine clearance ≤50 ml/min) Treatment with anti-obesity drugs or glucagon-like peptide-1 receptor agonists (GLP-1RAs) 3 months prior to enrolment Non-compliance with follow-up visits.
Facility Information:
Facility Name
University of Sadat City
City
El Sadat
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

We'll reach out to this number within 24 hrs